Background：At present, NCCN guidelines recommend taxane-based chemotherapy drugs or bevacizumab as the first-line treatment for malignant vascular-origin tumors, but efficacy is limited. Our center has initiated a research to assess the efficacy and safety of albumin-bound paclitaxel combined with bevacizumab in advanced, unresectable, metastatic vascular-origin tumors.
Methods：Our study plans to enroll 20 patients with histologically confirmed stage IV malignant vascular-origin tumors, aged 18 to 75 years, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. These patients have not received prior systemic therapy. Patients receive the following treatment: albumin-bound paclitaxel combined with bevacizumab until disease progression, intolerable toxicity, or death. The primary endpoint is objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), with secondary endpoints including safety, disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Results：As of May 15, 2025, a total of 14 patients have been enrolled in this study. All participants received albumin-bound paclitaxel combined with bevacizumab treatment. All 14 patients underwent at least one radiologic assessment, with 2 patients (14.3%) achieving partial response (PR), resulting in an ORR of 14.3%. Additionally, stable disease (SD) was observed in 11 patients (78.6%), yielding a DCR of 92.9%. One patient (7.1%) experienced disease progression (PD). Both PFS and OS have not yet been reached. The primary grade 3 adverse events included vomiting and leukopenia, occurring in 4 patients (28.6%). No grade 4 or 5 adverse events were reported.
Conclusion: Albumin-bound paclitaxel combined with bevacizumab demonstrates promising efficacy and safety in patients with advanced malignant vascular-origin tumors, however, which requires further validation through large-scale clinical research.